Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
14.39
-0.27 (-1.84%)
At close: Aug 13, 2026, 4:00 PM EDT
14.20
-0.19 (-1.32%)
Pre-market: Aug 14, 2026, 9:02 AM EDT
Design Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
900.55M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 450.89M |
| Geron | 204.56M |
| Arbutus Biopharma | 181.72M |
| Theravance Biopharma | 104.31M |
| Kura Oncology | 77.23M |
| Omeros | 38.42M |
| Aclaris Therapeutics | 8.22M |
DSGN News
- 11 days ago - Design Therapeutics reports Q2 EPS (32c), consensus (34c) - TheFly
- 11 days ago - Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 11 days ago - Design Therapeutics Quarterly report: Q2 2026 - Filings
- 11 days ago - Design Therapeutics Earnings release: Q2 2026 - Filings
- 6 weeks ago - Design Therapeutics initiates patient dosing in DT-818 trial - TheFly
- 6 weeks ago - Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1 - GlobeNewsWire
- 2 months ago - Design Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Design Therapeutics Slides: Corporate presentation - Filings